- Home
- DSM vs LXRX Comparison
DSM vs LXRX Comparison
Compare DSM & LXRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSM
- LXRX
- Stock Information
- Founded
- DSM 1989
- LXRX 1995
- Country
- DSM United States
- LXRX United States
- Employees
- DSM N/A
- LXRX N/A
- Industry
- DSM Investment Managers
- LXRX Biotechnology: Pharmaceutical Preparations
- Sector
- DSM Finance
- LXRX Health Care
- Exchange
- DSM Nasdaq
- LXRX Nasdaq
- Market Cap
- DSM 301.0M
- LXRX 273.9M
- IPO Year
- DSM N/A
- LXRX 2000
- Fundamental
- Price
- DSM $5.86
- LXRX $0.79
- Analyst Decision
- DSM
- LXRX Buy
- Analyst Count
- DSM 0
- LXRX 2
- Target Price
- DSM N/A
- LXRX $4.00
- AVG Volume (30 Days)
- DSM 161.7K
- LXRX 5.8M
- Earning Date
- DSM 01-01-0001
- LXRX 03-10-2025
- Dividend Yield
- DSM 3.97%
- LXRX N/A
- EPS Growth
- DSM N/A
- LXRX N/A
- EPS
- DSM N/A
- LXRX N/A
- Revenue
- DSM N/A
- LXRX $5,229,000.00
- Revenue This Year
- DSM N/A
- LXRX $842.94
- Revenue Next Year
- DSM N/A
- LXRX $19.76
- P/E Ratio
- DSM N/A
- LXRX N/A
- Revenue Growth
- DSM N/A
- LXRX 886.60
- 52 Week Low
- DSM $4.69
- LXRX $0.62
- 52 Week High
- DSM $6.05
- LXRX $3.73
- Technical
- Relative Strength Index (RSI)
- DSM 47.31
- LXRX 43.11
- Support Level
- DSM $5.79
- LXRX $0.68
- Resistance Level
- DSM $5.86
- LXRX $1.08
- Average True Range (ATR)
- DSM 0.05
- LXRX 0.12
- MACD
- DSM 0.01
- LXRX -0.00
- Stochastic Oscillator
- DSM 70.53
- LXRX 15.36
About DSM BNY Mellon Strategic Municipal Bond Fund Inc.
BNY Mellon Strategic Municipal Bond Fund, Inc. is a diversified closed-end management investment company. Its investment objective is to seek to maximize current income exempt from federal income tax to the extent consistent with the preservation of capital.
About LXRX Lexicon Pharmaceuticals Inc.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain; and sotagliflozin, an orally-delivered small molecule drug candidate, as a treatment for heart failure and type 1 diabetes.